ClinicalTrials.gg
CompletedNCT04009265Updated Oct 28, 2026

Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma

A Phase 3 interventional study of adjuvant treatment in Esophageal Squamous Cell Carcinoma, sponsored by Fujian Medical University Union Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Fujian Medical University Union Hospital · Phase 3, Interventional, and Treatment

How we know

Updated Oct 28, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 402 studies in Esophageal Squamous Cell Carcinoma with a site in China — 175 open to participants now, 214 under way, 32 of them phase 3. Esophageal Squamous Cell Carcinoma · China.

Enrollment
98th of 352
145 · median 70
Started
2019
with 33 others
Phase 3
52 of 402
20 open now
Registered
103rd of 402
by date

Among the 402 studies in Esophageal Squamous Cell Carcinoma with a site in China, this one is the 98th largest by enrollment of the 352 interventional ones that give a count, is one of 34 that started in 2019, is one of 52 in phase 3, and was the 103rd registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

175 of the 402 studies in Esophageal Squamous Cell Carcinoma with a site in China are open now. Recruiting first, the newest first:

170 more — sign in →

All 175 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 402 studies in Esophageal Squamous Cell Carcinoma with a site in China, or all of them as a file.
02

Study summary

A multi-center prospective randomized controlled study was conducted to compare the effects of adjuvant chemotherapy, chemoradiotherapy and surgery alone for the patients with esophageal cancer.

Read the detailed description

A multi-center prospective randomized controlled study was conducted to compare the effects of adjuvant chemotherapy, chemoradiotherapy and surgery alone on the overall survival rate (OS) and disease-free survival (DFS) of patients with pN1-2 (pT1b-3N1-2M0) thoracic esophageal squamous cell carcinoma, and to observe the safety, side effects of adjuvant therapy and the impact on the quality of life of patients after operation.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma

Keywords

  • esophageal squamous cell carcinoma
  • adjuvant chemotherapy
  • adjuvant chemoradiotherapy
  • surgery
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants volunteer to participate the study and signed the .
  2. Surgical methods: Radical resection of tumors (R0) was performed, and pathological examination confirmed the diagnosis of thoracic esophageal squamous cell carcinoma.
  3. No antineoplastic treatments before operation.
  4. According to the 8th edition of AJCC staging, pN1-2 (pT1b-3N1-2M0) stage of esophageal cancer;
  5. WHO PS score: 0-1;
  6. Age and gender: 18-75 years old, male and female unlimited;
  7. Laboratory examination within one week before the treatment confirmed that the cardiac, hepatic and renal functions met the requirements.

Exclusion criteria

Exclusion Criteria:

  1. The surgical approach is left thoracic approach;
  2. Patients with severe postoperative complications who cannot receive therapy;
  3. Received other anti-tumor treatment before enrollment; At the same time, patients with malignant tumors of other sites were excluded, except non-melanoma skin cancer, in-situ cervical cancer or cured early prostate cancer.
  4. Abnormal coagulation function, bleeding tendency (such as active gastrointestinal ulcer) or receiving thrombolytic or anticoagulant treatment;
  5. Patients with original severe heart disease, including congestive heart failure, uncontrollable high-risk arrhythmia, unstable angina pectoris, myocardial infarction within half a year, severe heart valve disease and intractable hypertension; Severe hepatic and renal insufficiency;
  6. Patients with uncontrollable neurological, mental illness or mental disorder, poor compliance, and inability to cooperate or describe treatment response;
  7. Known or suspected allergy to chemotherapeutic drugs.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    Chemotherapy

    Docetaxel 75mg/m2, 3w, 2cycles. DDP 75mg/m2, 3wl, 2cycles.

    Combination Product: adjuvant treatment

  • Experimental
    Chemoradiotherapy

    5040cGy, 180cGy/d, 28F Concurrent Docetaxel 60mg/m2, 3w, 2cycles DDP 60mg/m2, 3w, 2cycles

    Combination Product: adjuvant treatment

  • No intervention
    Surgery alone

    Surgery alone, no adjuvant treatment.

Interventions

  • Combination productadjuvant treatment

    adjuvant treatments include chemotherapy or chemoradiotherapy

06

What researchers measure

Primary outcomes

  1. Overall Survival

    overall survival rate of each arms

    Time frame: 3-year overall survival

  2. Overall Survival

    overall survival rate of each arms

    Time frame: 5-year overall survival

Secondary outcomes

  1. Disease Free Survival

    Disease free survival rate of each arms

    Time frame: 3-year disease free survival

  2. Disease Free Survival

    Disease free survival rate of each arms

    Time frame: 5-year disease free survival

  3. Adverse Events

    Number and degree of Adverse Events based on Common Toxicity Criteria for Adverse Effects(CTCAE)

    Time frame: 1 year

  4. Scores of Quality of Life

    Assess the quality of life based on EORTC QLQ-C30 and OES18

    Time frame: 5 years

07

Study locations

1 site
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Sep 2024, 61 months.

Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's 61 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Jul 2022 → Sep 2024 and completion Jul 2027 → Mar 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2019
First posted
Jul 5, 2019
StartActual
Aug 23, 2019
Primary completionActual
Sep 30, 2024was Jul 2022
CompletionActual
Mar 10, 2025was Jul 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 28, 2026
Primary completion
Jul 1, 2022→Sep 30, 2024 (actual)
Oct 28, 2026
Study completion
Jul 1, 2027→Mar 10, 2025 (actual)
Oct 28, 2026
Enrollment
819 (estimated)→145 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Completed
    Primary completion Jul 1, 2022→Sep 30, 2024 (now actual)
    Study completion Jul 1, 2027→Mar 10, 2025 (now actual)
    Enrollment 819 (estimated)→145 (actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04009265
Responsible party
Sponsor
First posted
Jul 5, 2019
Start date
Aug 23, 2019
Primary completion
Sep 30, 2024
Completion
Mar 10, 2025
Last update
Oct 28, 2026

Study contacts

Chun Chen, MD
study director · Fujian Medical University Union Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion